FBRX 8-K SEC Filing Analysis

Latest settled — T+20d ⚠ clustered

FBRX ▼ -21.77% at T+20d

NEUTRAL call ✗ call lost -21.77% · α vs SPY -29.34% · entry $33.90 → $26.52

Next anchor: T+60d in 21d

Last close $17.56 (close Jun 12) · -48.20% from $33.90 entry

Entry anchored
Apr 8, 03:58 PM ET
via Databento tick

T+1d

+3.51%

call +3.51% · α +3.57%

$35.09

settled 2mo ago

T+5d

-7.29%

call -7.29% · α -10.47%

$31.43

settled 2mo ago

T+20d

-21.77%

call -21.77% · α -29.34%

$26.52

settled 6w ago

T+60d

—

call — · α —

—

in 21d

Price Chart

Loading chart...

Executive Summary

Forte Biosciences announced a $150 million public offering of 5.7 million shares at $26.27 per share, with a 30-day option for underwriters to purchase an additional 856,490 shares. Concurrently, argenx BV made a strategic investment in the company. The proceeds will fund clinical development and general corporate purposes.

Key Financial Metrics

Deal Value

$150.0M

Actionable Insight

Monitor for potential stock price pressure from the dilution of new shares, though the strategic investment by argenx BV may provide some offsetting support. The capital infusion strengthens the company's position to advance its clinical programs.

Key Facts

Forte Biosciences priced a public offering of 5,709,936 shares at $26.27 per share
Underwriters have a 30-day option to purchase up to an additional 856,490 shares
Gross proceeds expected to be approximately $150 million before underwriting discounts and commissions
Net proceeds estimated at $141 million ($162 million if full option exercised), to be used for clinical development and general corporate purposes
Strategic investment made by argenx BV as part of the offering

Financial Impact

Raises approximately $141 million in net proceeds (up to $162 million if full option exercised), diluting existing shareholders

dilutioncashdebt

Risk Factors

Dilution from new share issuance could pressure stock price
Market conditions could affect the successful closing of the offering
Execution risk in clinical development despite additional funding

Market Snapshot

Exchange

Nasdaq

Sector

Pharmaceutical Preparations

Documents Analyzed

This report is based on 7 SEC documents filed with EDGAR.

Document	Accession Number
8-K Filing (Primary)	0001193125-26-148796
Document: d128424d8k.htm	0001193125-26-148796
Document: d128424dex51.htm	0001193125-26-148796
Document: d128424dex991.htm	0001193125-26-148796
Document: 0001193125-26-148796-index-headers.html	0001193125-26-148796
Document: 0001193125-26-148796-index.html	0001193125-26-148796
Document: 0001193125-26-148796.txt	0001193125-26-148796

8 reports for FBRX

T+1T+5T+20T+60

67% Hit rate 2 of 3 directional calls best @ T+20▲ +21.77%Apr 8, 2026

Filters

Reports for FBRX — sortable, filterable
	Type				Now
Jun 11, 2026 4d ago	EFFECT BEARISH ★ 6/10	$16.86 awaiting T+1	awaiting T+1	—	$17.56 (−4.15%)
Jun 6, 2026 9d ago	S-3/A BEARISH ★ 6/10	$16.37 awaiting T+1	awaiting T+1	—	$17.56 (−7.27%)
Jun 2, 2026 12d ago	S-3 BEARISH ★ 6/10	$17.00 $16.69	▲ +1.82%	▲ +2.22%	$17.56 (−3.29%)
Jun 2, 2026 12d ago	8-K NEUTRAL ★ 3/10	$17.00 $16.69	▼ −1.82%	▼ −2.23%	$17.56 (+3.29%)
May 14, 2026 4w ago	8-K MIXED ★ 6/10	$23.11 $20.97	▼ −9.26%	▼ −9.20%	$17.56 (−24.02%)
Apr 9, 2026 9w ago	8-K NEUTRAL ★ 5/10	$33.90 $35.09	▲ +3.51%	▲ +3.57%	$17.56 (−48.20%)
Apr 8, 2026 9w ago	424B5 BEARISH ★ 5/10	$33.90 $35.09	▼ −3.51%	▼ −3.57%	$17.56 (+48.20%)
Apr 1, 2026 10w ago	8-K BEARISH ★ 7/10	$24.86 $25.58	▼ −2.90%	▼ −2.82%	$17.56 (+29.36%)

US Market Status

Market Closed — Opens in 4h 33m

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access